Journal of Advanced Pharmaceutical Technology & Research

REVIEW ARTICLE
Year
: 2021  |  Volume : 12  |  Issue : 3  |  Page : 215--221

Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review


Subodh Kumar, Manoj Kumar Saurabh, Vikas Maharshi 
 Department of Pharmacology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India

Correspondence Address:
Dr. Vikas Maharshi
Department of Pharmacology, All India Institute of Medical Sciences, Deoghar, Jharkhand
India

Search for an effective and safe vaccine to prevent transmission of current pandemic is an unmet need. This study reviews and compares the available early phase clinical data of vaccine candidates which have reached phase 3 of clinical development. The latest update of “DRAFT landscape of coronavirus (CoV) disease 2019 candidate vaccines (October 2, 2020)” released by the World Health Organization was accessed to identify the potential vaccine candidates. The full text articles (published and/or preprint) of data of early clinical trials of the selected vaccines were accessed from the links provided in the same document, PubMed and/or medRxiv.com. After extraction and synthesis, the data were critically evaluated for the study efficacy and safety outcomes. Of the total 193 candidate vaccines 10 were found to reach phase 3 of the clinical development. Nine of these were included in the evaluation process. In all of the included studies, immunogenicity and serious adverse events/local or systemic adverse events/laboratory parameters abnormality was considered as efficacy and safety outcomes respectively. Immunogenicity response with most of the vaccines was either higher than or similar to the respective controls except one (recombinant adenovirus type 26 COV2 [Ad26.COV2.S]) for which it was less than that in control. Overall adverse events (related and/or unrelated) were more with vaccines than those with respective control(s) in three studies, in other two, these were similar whereas in one study, the events were less in the vaccine group than in control group and in the rest, data described were descriptive only without any mention for the same for the control. In conclusion all studies showed immunogenic response to target protein of severe acute respiratory syndrome CoV-2 and which was higher than the respective control except for Ad26.CoV2.S. Many of the vaccines caused more adverse events than the controls, however most were mild and transient and/or manageable.


How to cite this article:
Kumar S, Saurabh MK, Maharshi V. Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review.J Adv Pharm Technol Res 2021;12:215-221


How to cite this URL:
Kumar S, Saurabh MK, Maharshi V. Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review. J Adv Pharm Technol Res [serial online] 2021 [cited 2021 Oct 26 ];12:215-221
Available from: https://www.japtr.org/article.asp?issn=2231-4040;year=2021;volume=12;issue=3;spage=215;epage=221;aulast=Kumar;type=0